Cystic Fibrosis: Once-A-Day Antibiotic Durable

A once-daily inhaled antibiotic appeared to offer long-term benefits in cystic fibrosis (CF) patients with Pseudomonas aeruginosa infection, researchers said here.

In an extension of a trial that compared investigational liposomal amikacin for inhalation (Arikace) Continue reading Cystic Fibrosis: Once-A-Day Antibiotic Durable

Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

– Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations –

SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ — PTC Therapeutics, Inc. PTCT -2.85% today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation Continue reading Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

Vertex says cystic fibrosis drugs shown to boost lung function

(Reuters) – Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, Continue reading Vertex says cystic fibrosis drugs shown to boost lung function

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

Xenetic Biosciences, Inc. XBIO -4.00% , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the positive results from its Phase I clinical trial of PulmoXenTM for the Continue reading Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema), will also be tested in a new round of clinical trials for cystic fibrosis this summer. Continue reading New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

Gentamicin belongs to the amino glycoside class of antibiotics and is used to treat mostly gram negative bacterial infections, including severe ones like pyelonephritis, biliary sepsis, endocarditis, and cystic fibrosis among others. It is a bactericidal Continue reading Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

Attention CF Patients With Persistent MRSA Lung Infection

A Phase 2 clinical trial to evaluate the safety and efficacy of an
inhaled anti-MRSA antibiotic is enrolling now.

MRSA + CF
The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently at 27% in the U.S. Recent publications indicate that chronic Continue reading Attention CF Patients With Persistent MRSA Lung Infection

N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

BOULDER, Colo., March 12, 2014 /PRNewswire/ — N30 Pharmaceuticals, Inc. (“N30 Pharma”) announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). Continue reading N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

CF and MRSA Clinical Trial by Savara Pharmaceutical

CLINICAL TRIAL
Are you a CF patient with persistent MRSA lung infection? If so, you may be interested in a Phase 2 clinical trial designed to evaluate the safety and efficacy of AeroVanc (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic Continue reading CF and MRSA Clinical Trial by Savara Pharmaceutical

New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements

The vast majority of Cystic Fibrosis treatments currently approved by the Food and Drug Administration focus on managing and curtailing symptoms of the disease rather than treating its underlying causes. However, a new pharma report from GBI Research Continue reading New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements